Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
10% Owner | Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% |
Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% | |
Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% | |
Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% | |
Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% | |
Nautilus BiotechnologyNAUT | Open-market sale | 06/02 | 06/04 | 5,000,000 sh2 trades | $2.35avg. | $11,750,000 | −83.7% | |
Sujal M. PatelCEO, President, and Secretary | Nautilus BiotechnologyNAUT | Open-market buy | 03/04 | 03/04 | 25,000 sh | $2.61 | $65,250 | +0.2% |
Kentaro SuzukiChief Marketing Officer | Nautilus BiotechnologyNAUT | Open-market buy | 25/11/06 | 25/11/10 | 4,000 sh | $1.49 | $5,960 | No record |
Nautilus BiotechnologyNAUT | Open-market buy | 25/09/05–25/09/08 | 25/09/09 | 200,000 sh2 trades | $0.67avg. | $134,835 | +2.0% | |
Matthew B. MurphyGeneral Counsel | Nautilus BiotechnologyNAUT | Open-market buy | 25/09/04 | 25/09/05 | 20,000 sh | $0.64 | $12,800 | +36.9% |
Anna MowryCFO and Treasurer | Nautilus BiotechnologyNAUT | Open-market buy | 25/05/29 | 25/06/02 | 15,000 sh | $0.77 | $11,550 | +22.1% |
Nautilus BiotechnologyNAUT | Open-market buy | 25/05/08–25/05/12 | 25/05/12 | 13,500 sh2 trades | $0.73avg. | $9,855 | +0.1% | |
Nautilus BiotechnologyNAUT | Open-market buy | 25/03/19–25/03/20 | 25/03/21 | 77,233 sh2 trades | $0.99avg. | $76,700 | +0.8% | |
Mary E. GodwinSenior VP, Operations | Nautilus BiotechnologyNAUT | Open-market sale | 24/09/23 | 24/09/25 | 47,031 sh | $2.87 | $134,978.97 | −100.0% |
Mary E. GodwinSenior VP, Operations | Nautilus BiotechnologyNAUT | Open-market sale | 24/09/17 | 24/09/18 | 35,000 sh | $2.85 | $99,750 | −100.0% |
Nautilus BiotechnologyNAUT | Open-market buy | 24/03/08–24/03/11 | 24/03/11 | 14,474 sh2 trades | $2.87avg. | $41,470.66 | +0.1% | |
Nautilus BiotechnologyNAUT | Open-market buy | 24/03/05–24/03/07 | 24/03/07 | 35,526 sh3 trades | $2.79avg. | $99,132.21 | +0.4% |
